Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
0.872
-0.058 (-6.20%)
At close: Dec 20, 2024, 4:00 PM
0.910
+0.038 (4.32%)
After-hours: Dec 20, 2024, 5:58 PM EST
Clearside Biomedical Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for CLSD stock have an average target of 5.33, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 511.03% from the current stock price of 0.87.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 15, 2024.
Analyst Ratings
The average analyst rating for CLSD stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +587.84% | Nov 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +587.84% | Nov 14, 2024 |
| Needham | Needham | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +587.84% | Nov 13, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +587.84% | Oct 14, 2024 |
| Needham | Needham | Strong Buy Maintains $4 → $6 | Strong Buy | Maintains | $4 → $6 | +587.84% | Oct 10, 2024 |
Financial Forecast
Revenue This Year
1.59M
from 8.23M
Decreased by -80.71%
Revenue Next Year
3.05M
from 1.59M
Increased by 91.87%
EPS This Year
-0.48
from -0.53
EPS Next Year
-0.46
from -0.48
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.8M | 16.9M | 34.3M | |||
| Avg | 1.6M | 3.0M | 11.4M | |||
| Low | 1.4M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -78.3% | 967.6% | 1,025.9% | |||
| Avg | -80.7% | 91.9% | 274.8% | |||
| Low | -83.3% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.44 | -0.38 | -0.37 | |||
| Avg | -0.48 | -0.46 | -0.50 | |||
| Low | -0.49 | -0.58 | -0.72 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.